Literature DB >> 14704740

Adipose tissue, insulin action and vascular disease: inflammatory signals.

J S Yudkin1.   

Abstract

Insulin resistance, both in nondiabetic and diabetic subjects, is frequently associated with obesity, particularly an excess of central fat. Many of the features that have been ascribed to the metabolic or insulin-resistance syndrome are also more commonly found in obese subjects. These phenotypes include diabetic dyslipidaemia, elevation of levels of plasminogen activator inhibitor-1, microalbuminuria and endothelial dysfunction. More recently, features of acute-phase activation and low-grade inflammation, including elevated levels of fibrinogen, C-reactive protein and interleukin-6, have been associated with (central) obesity. Adipose tissue generation of cytokines has been shown in vitro and in vivo, and a number of novel cytokine-like molecules, collectively termed adipocytokines, have been identified as adipocyte products. While several of these, such as tumour necrosis factor-alpha, may act predominantly in autocrine or paracrine fashion, others are released into the systemic circulation, acting as signalling molecules to remote tissues, including liver, skeletal muscle and endothelium. A clearer understanding of adipose tissue signalling, and its contribution to the state of low-grade inflammation of obesity, will require physiological, as well as cellular and molecular, studies.

Entities:  

Mesh:

Year:  2003        PMID: 14704740     DOI: 10.1038/sj.ijo.0802496

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  79 in total

1.  Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture.

Authors:  Bohan Wang; Paul Trayhurn
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

2.  Increased Rho kinase activity in a Taiwanese population with metabolic syndrome.

Authors:  Ping-Yen Liu; Jyh-Hong Chen; Li-Jen Lin; James K Liao
Journal:  J Am Coll Cardiol       Date:  2007-04-02       Impact factor: 24.094

Review 3.  Considerations for dosing immunoglobulin in obese patients.

Authors:  J P Hodkinson
Journal:  Clin Exp Immunol       Date:  2017-04-17       Impact factor: 4.330

Review 4.  Obesity and pregnancy complications.

Authors:  Hugh E Mighty; And Jenifer O Fahey
Journal:  Curr Diab Rep       Date:  2007-08       Impact factor: 4.810

5.  Adipokine expression and secretion by canine adipocytes: stimulation of inflammatory adipokine production by LPS and TNFalpha.

Authors:  Vivien H Ryan; Alexander J German; I Stuart Wood; Leif Hunter; Penelope Morris; Paul Trayhurn
Journal:  Pflugers Arch       Date:  2010-05-15       Impact factor: 3.657

Review 6.  Adipose tissue and vascular inflammation in coronary artery disease.

Authors:  Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò
Journal:  World J Cardiol       Date:  2014-07-26

Review 7.  Inflammation, insulin resistance, and obesity.

Authors:  Patrizia Ferroni; Stefani Basili; Angela Falco; Giovanni Davì
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

Review 8.  Maternal obesity, inflammation, and fetal skeletal muscle development.

Authors:  Min Du; Xu Yan; Jun F Tong; Junxing Zhao; Mei J Zhu
Journal:  Biol Reprod       Date:  2009-06-10       Impact factor: 4.285

9.  Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction.

Authors:  Kai Sun; Nils Halberg; Mahmood Khan; Ulysses J Magalang; Philipp E Scherer
Journal:  Mol Cell Biol       Date:  2012-12-17       Impact factor: 4.272

10.  Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss.

Authors:  Eva Solá; Ana Jover; Antonio López-Ruiz; María Jarabo; Amparo Vayá; Carlos Morillas; Marcelino Gómez-Balaguer; Antonio Hernández-Mijares
Journal:  Obes Surg       Date:  2008-12-03       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.